NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SI
Post# of 137
(Total Views: 166)
Posted On: 10/24/2022 3:52:59 PM
NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine (‘MDMA’), has steadily progressed from pilot studies confirming safety and feasibility through to early phase trials providing preliminary evidence of clinical efficacy. Silo Pharma has been an early pioneer of these research studies through its commitment to developing innovative solutions to address a variety of underserved conditions, many of which are being carried out in partnership with leading medical universities across the globe.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine (‘MDMA’), has steadily progressed from pilot studies confirming safety and feasibility through to early phase trials providing preliminary evidence of clinical efficacy. Silo Pharma has been an early pioneer of these research studies through its commitment to developing innovative solutions to address a variety of underserved conditions, many of which are being carried out in partnership with leading medical universities across the globe.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)SILO Pharma Inc. (SILO) Stock Research Links
Scroll down for more posts ▼